EA015535B1 - Формуляция бензимидазола - Google Patents

Формуляция бензимидазола Download PDF

Info

Publication number
EA015535B1
EA015535B1 EA200800290A EA200800290A EA015535B1 EA 015535 B1 EA015535 B1 EA 015535B1 EA 200800290 A EA200800290 A EA 200800290A EA 200800290 A EA200800290 A EA 200800290A EA 015535 B1 EA015535 B1 EA 015535B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pantoprazole
alkaline
dry
alkaline substance
salt
Prior art date
Application number
EA200800290A
Other languages
English (en)
Russian (ru)
Other versions
EA200800290A1 (ru
Inventor
Поул Бертелсен
Педер Мор Олсен
Original Assignee
Никомед Данмарк Апс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Никомед Данмарк Апс filed Critical Никомед Данмарк Апс
Publication of EA200800290A1 publication Critical patent/EA200800290A1/ru
Publication of EA015535B1 publication Critical patent/EA015535B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EA200800290A 2005-07-11 2006-07-11 Формуляция бензимидазола EA015535B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200501019 2005-07-11
US72785505P 2005-10-19 2005-10-19
PCT/DK2006/000409 WO2006105798A2 (fr) 2005-07-11 2006-07-11 Formulation de benzimidazole

Publications (2)

Publication Number Publication Date
EA200800290A1 EA200800290A1 (ru) 2008-08-29
EA015535B1 true EA015535B1 (ru) 2011-08-30

Family

ID=37492042

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800290A EA015535B1 (ru) 2005-07-11 2006-07-11 Формуляция бензимидазола

Country Status (5)

Country Link
EP (1) EP1901719A2 (fr)
AU (1) AU2006230974C1 (fr)
CA (1) CA2614526A1 (fr)
EA (1) EA015535B1 (fr)
WO (1) WO2006105798A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
TWI441658B (zh) 2008-03-11 2014-06-21 Takeda Pharmaceutical 口腔崩解固體製劑
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
TR201000948A1 (tr) * 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN103479593B (zh) * 2013-05-10 2014-10-08 青岛双鲸药业有限公司 一种奥美拉唑肠溶片的制备方法
CN103386133A (zh) * 2013-07-09 2013-11-13 重庆莱美药业股份有限公司 一种质子泵抑制剂的口腔速溶制剂及其制备方法
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104825414B (zh) * 2015-05-07 2018-11-16 山东新时代药业有限公司 一种稳定的s-泮托拉唑钠肠溶片
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (fr) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. Traitement du carcinome hépatocellulaire
CN113318079B (zh) * 2021-05-13 2024-01-09 江西博莱大药厂有限公司 一种提高三氯苯达唑颗粒溶出度的方法及其溶出度检测方法
CN115645373B (zh) * 2022-12-24 2024-01-30 山东理工职业学院 一种奥美拉唑钠片的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050019A1 (fr) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Formes posologiques pharmaceutiques orales stables
EP1004305A1 (fr) * 1998-04-20 2000-05-31 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
WO2004075881A1 (fr) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Compositions pharmaceutiques stables de rabeprazole et leurs procedes de fabrication
WO2004112756A1 (fr) * 2003-06-26 2004-12-29 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
WO2005009410A2 (fr) * 2003-07-17 2005-02-03 Dr. Reddy's Laboratories, Inc. Compositions pharmaceutiques a revetement gonflant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050019A1 (fr) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Formes posologiques pharmaceutiques orales stables
EP1004305A1 (fr) * 1998-04-20 2000-05-31 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
WO2004075881A1 (fr) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Compositions pharmaceutiques stables de rabeprazole et leurs procedes de fabrication
WO2004112756A1 (fr) * 2003-06-26 2004-12-29 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
WO2005009410A2 (fr) * 2003-07-17 2005-02-03 Dr. Reddy's Laboratories, Inc. Compositions pharmaceutiques a revetement gonflant

Also Published As

Publication number Publication date
AU2006230974C1 (en) 2012-02-02
CA2614526A1 (fr) 2006-10-12
EA200800290A1 (ru) 2008-08-29
WO2006105798A3 (fr) 2006-12-07
AU2006230974A1 (en) 2006-10-12
AU2006230974B2 (en) 2011-09-29
EP1901719A2 (fr) 2008-03-26
WO2006105798A2 (fr) 2006-10-12

Similar Documents

Publication Publication Date Title
EA015535B1 (ru) Формуляция бензимидазола
EA022168B1 (ru) Способ получения уплотненного промежуточного продукта дималеата bibw 2992 и твердые таблетки, полученные из такого продукта
JP6679495B2 (ja) 免疫抑制製剤
EP2590630B1 (fr) Forme de dosage orale contenan deferasirox
JPH11508587A (ja) 難溶性薬物の制御放出製剤
AU2014225449B2 (en) Stabilization of moisture-sensitive drugs
CA2704646A1 (fr) Comprimes a liberation prolongee contenant de l'hydromorphone
EP2988733B1 (fr) Composition pharmaceutique contenant du macitentan cristallin
Sun et al. A microcrystalline cellulose based drug-composite formulation strategy for developing low dose drug tablets
US8808739B2 (en) Orodispersible tablet containing compacted sildenafil base
EA023340B1 (ru) Композиция ропинирола
WO2012000926A1 (fr) Composés d'inclusion silodosine et cyclodextrine
EP3184103A1 (fr) Composition pharmaceutique comprenant de l'atorvastatine ou un sel de celui-ci
WO2003055467A1 (fr) Formes posologiques de simvastatine
Kestur et al. Excipients for conventional oral solid dosage forms
EP2806860B1 (fr) Composition pharmaceutique contenant du tosylate sorafenib cristallin
US20070020334A1 (en) Benzimidazole formulation
EA016579B1 (ru) Твердый фармацевтический препарат, содержащий гидрохлорид ирбесартана, и способ его изготовления
US10016471B2 (en) Solid pharmaceutical compositions of brown algae
EP4279075A1 (fr) Composition pharmaceutique contenant de l'elagolix
Sathvik et al. Formulation and Evaluation of Atenolol Floating Tablets using Polymers
Sawant et al. In-vitro release kinetic study of mosapride citrate dihydrate from sustained release matrix tablet containing two different viscosity grades of HPMC
TW202500156A (zh) 包含具有ｇ１２ｃ突變的ｋ－ｒａｓ蛋白之抑制劑的固體調配物及製備方法
KR20240055103A (ko) 벰페도산의 약학 조성물
Kestur et al. EXCIPIENTS ORAL SOLID FOR DOSAGE CONVENTIONAL FORMS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU